Clinical trials: Genome
Non-small Cell Lung Cancer Metastatic
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
- Trial name
- DEEP-Lung-IV (NCT04994795)
- Testing
- Predictive models (data collection)
- Where
- 30 sites in United States, Brazil and 6 more
- Volunteers
- 4,000 people
- Sponsor
- Sophia Genetics SAS
Harboring of Unexpected Genetic Variant
Reverse Phenotyping Core
Background: Genes tell a person's body how to grow and work. All people have variations in their genes. Some of these cause differences that show up in a person's traits or their health, others do not.
- Trial name
- NCT03632239
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Afatinib Genomic Landscape
The investigators propose to conduct a pilot feasibility study of single agent afatinib in patients with previously untreated metastatic EGFR (epidermal growth factor receptor) mutant adenocarcinoma of the lung (NSCLC = non-small…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-small Lung Cancer
- Trial name
- NCT02491775
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Dietary Fiber, Gastrointestinal Microbiome
Luxembourgish Fiber Cohort
Many human populations across the world are deficient in the intake of dietary fiber. This decline in fiber consumption parallels an increase in prevalence of a multitude of diseases (e.g. colorectal cancer, multiple sclerosis).
- Conditions
- Dietary Fiber, Gastrointestinal Microbiome, Healthy Volunteers
- Trial name
- Lux-FiCo (NCT04352231)
- Testing
- High Fiber Diet Intervention, Low Fiber Diet Intervention
- Where
- 2 sites in Luxembourg
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Luxembourg Institute of Health
Non-Small Cell Lung Cancer
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced…
- Trial name
- NCT07464327
- Testing
- HS-20093, Docetaxel
- Volunteers
- 450 people
- Sponsor
- Hansoh BioMedical R&D Company
Birth Defect, Newborn; Fit
The Pilot Study of High-throughput Sequencing in Neonatal Birth Defects
In China, birth defects can reach as high as 5.6%, about 900,000 new cases of birth defects are added each year, making it the second cause of death for infants, with a total death rate of 19.1%.
- Conditions
- Birth Defect, Newborn; Fit, Genetic Diseases, Multiple Malformation
- Trial name
- NCT03984266
- Testing
- NGS panel
- Where
- China
- Volunteers
- 3,423 people
- Sponsor
- Children's Hospital of Chongqing Medical University
Adverse Effect of Other Antipsychotics and Neuroleptics
Adverse Events and Genomics in Schizophrenia
The purpose of this study is to find genes that predict whether or not a person will develop side effects to antipsychotic medications, such as weight gain, blood sugar dysregulation, or immune cell abnormalities.
- Trial name
- AEGIS (NCT01966588)
- Testing
- Blood samples for whole genomic/transcriptomic sequencing, UKU Side Effect Rating Scale
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Cancer, Breast Cancer
Genomic Investigation of Unusual Responders
Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic…
- Conditions
- Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- GENIUS (NCT03740503)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Efficacy
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected…
- Trial name
- NCT06237205
- Testing
- Niraparib
- Volunteers
- 33 people
- Sponsor
- Korea University Anam Hospital
Psychological Well-being and Immune Health Profile
The Genomic and Well-Being Impacts of an Extraverted Behavior Intervention
8-week randomized intervention (with 3-month follow-up) that examines the impact of increased sociable behavior on emotional well-being and immune health profile
- Trial name
- NCT07690605
- Testing
- Sociable (extraverted) behavior
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- University of California, Riverside
Respiratory Distress Syndrome, Adult, COVID-19
Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients
Pandemic SARS-CoV-2 (COVID-19) respiratory infection is responsible for more than 4,000 deaths, mainly (67%) secondary to acute respiratory distress syndromes (ARDS).
- Trial name
- COMETS (NCT04516486)
- Testing
- retrospective metagenomics on clinical samples collected during hospitalization
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes Mellitus, Diabetic Nephropathy
Study of Genome-associated Mechanisms of Diabetic Nephropathy and Evaluation of Nephroprotective Therapy in Patients With Type 2 Diabetes Mellitus in the Kazakh Population
The incidence of diabetes remains a serious global health issue, demanding close attention and the development of comprehensive strategies for prevention, early diagnosis, and effective treatment .
- Trial name
- NCT07038213
- Testing
- glycation genes, beta 2 microglobulin
- Where
- Kazakhstan
- Volunteers
- 100 people
- Sponsor
- Astana Medical University
Autism Spectrum Disorder
Genome Environment Microbiome and Metabolome in Autism Study
GEMMA is a multicenter longitudinal observational study that follows children who are genetically at-risk of developing autism for their first three years of life, seeking to identify potential biomarkers predictive of autism…
- Trial name
- GEMMA (NCT04271774)
- Where
- 3 sites in United States, Ireland and 1 more
- Volunteers
- 344 people
- Sponsor
- Massachusetts General Hospital
Healthy
Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations
Physicians know that their patients can react differently to the same medical treatment: for some of them, the drug will prove inefficient, whereas for others it might provoke side-effects, sometimes rather serious.
- Trial name
- NCT02789527
- Testing
- Phenotyping, Genotyping
- Where
- 4 sites in Czechia, Ethiopia and 2 more
- Volunteers
- 367 people, healthy volunteers welcome
- Sponsor
- Estella S. Poloni
Triple Negative Breast Cancer
Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer
The primary objective is to describe and discover new insights into the glucose, amino acid, and lipid metabolic dependencies of TNBC via nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo [1,2-13C] glucose-labeled…
- Trial name
- NCT03457779
- Testing
- Glucose
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Baylor Research Institute
Arteriovenous Malformations, Intracranial Aneurysm
Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm
Test single nucleotide polymorphisms (SNP's) in ruptured and unruptured aneurysm tissue to identify a genetic difference between the two types of aneurysms; and to test SNP's in arteriovenous malformation tissue to identify a…
- Conditions
- Arteriovenous Malformations, Intracranial Aneurysm, Subarachnoid Hemorrhage
- Trial name
- NCT01801488
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- State University of New York - Upstate Medical University
Dysbacteriosis
Longitudinal Study of the Human Intestinal Microbiome
The purpose of this study is to identify the human intestinal microbiota (microbes that live inside and on human bodies) in healthy adults over a 6-month period and to study the effect of an antibiotic on the intestinal…
- Trial name
- NCT00832286
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Early-Stage Breast Cancer
Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer
This multi-center randomized Phase II study assigned HER2-negative early-stage breast cancer patients to receive preoperative systemic chemotherapy in either a "genomic-guided" arm or a "non-guided arm." The "genomic-guided"…
- Trial name
- NCT00636441
- Testing
- Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Duke University
Infertility
Control Ovarian Stimulation Timing Test
IVF (in vitro fertilization) cycles fails more often than they succeed. Surprisingly very little effort is invested in defining the reasons for failure and possibly finding ways to improve the success on the next cycle.
- Trial name
- COST2 (NCT02397135)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Laval University
Myelodysplastic Syndromes
iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes
This open-label, randomized, parallel group phase II study will investigate the efficacy of computational biology-informed treatment vs.
- Trial name
- NCT03446638
- Testing
- FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction
- Where
- United States
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.